Results 191 to 200 of about 101,852 (311)

Combination Versus Monotherapy in Acute Anti‐LGI1 Encephalitis: A Real‐World Dose Optimization Analysis

Neuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
Combined IVIg and 500 mg/day IVMP achieve superior efficacy over monotherapies in anti‐LGI1 encephalitis, with optimal safety. Higher‐dose IVMP (1000 mg) accelerates response but increases adverse events, particularly in diabetic patients. Cognitive deficits persist post‐treatment, necessitating long‐term management.
Yao Tan, Ming Sun, Qinqin Liu, Beibei Huang, Chao Wu, Jie Lu, Donglin Zhu   +6 more
wiley   +1 more source

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs). [PDF]

Pituitary
Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Haberbosch L, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Schilbach K, Lely AJV, Wass JAH, Melmed S, Casanueva FF.   +18 more
europepmc   +1 more source

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

International Journal of Cancer, Volume 158, Issue 10, Page 2674-2683, 15 May 2026.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang, Jing‐jing Sun, Zhi Wan, Xiao‐yu Jing, Xia Guo, Ju Gao   +5 more
wiley   +1 more source

The HIT Network for Children and Adolescents With CNS Tumors Facilitates Improvements of Diagnostic Assessments, Multimodal Treatments, Individual Counseling, and Research in Germany, Austria, and Switzerland

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background The HIT network was established in 2000 to create a population‐based structure aiming to improve survival rates and reduce late effects for children with central nervous system (CNS) tumors by conducting comprehensive clinical trials.
Stefan Rutkowski, Michael C. Frühwald, Gudrun Fleischhack, Stephan Tippelt, Pablo Hernáiz‐Driever, Olaf Witt, Astrid Gnekow, Christof Kramm, Matthias Eyrich, Johannes E. A. Wolf, Hermann Müller, Carsten Friedrich, Uwe R. Kordes, Denise Obrecht‐Sturm, Petra Ketteler, Barbara von Zezschwitz, Pascal Johann, Dominik Sturm, Karoline Nemes, Stefan Schönberger, Till Milde, Brigitte Bison, Monika Warmuth‐Metz, Torsten Pietsch, Ulrich Schüller, Arend Koch, David Capper, Martin Hasselblatt, Christian Thomas, Christian Hagel, Stefan M. Pfister, Felix Sahm, David T. W. Jones, Martin U. Schuhmann, Jürgen Krauss, Pedram Emami, Ahmed El Damaty, Rolf D. Kortmann, Rudolf Schwarz, Jürgen Debus, Mechthild Krause, Fabian Pohl, Holger Ottensmeier, Lisa Bußenius, Katja Baust, Andreas Faldum, Cecile Ronckers, Desiree Grabow, Martin Benesch, Thomas Perwein, Karin Dieckmann, Irene Slavc, Johannes Gojo, Nicolas U. Gerber, André O. von Bueren, Katrin Scheinemann, Gabriele Calaminus, Beate Timmermann, Ulrich‐Wilhelm Thomale, Martin Mynarek   +59 more
wiley   +1 more source

Atherosclerosis enhances the efficacy of liposome-encapsulated bromocriptine in reducing the incidence of prolactinemia in pituitary tumors. [PDF]

J Nanobiotechnology
Zhang Z, Jia G, Wang Q, Yu Y, Tang X, Zheng H, Yang X, Xiao Y, Ou Y, Jiang J, Guo H, Wang Y, Li S.   +12 more
europepmc   +1 more source

Criterion‐Related Validity of the Neuropsychological Quick Assessment for Screening Cognitive, Motor, and Behavioral Impairments in Patients With Pediatric Brain Tumors: An Observational Pilot Study

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Neuropsychological complications may impair the qualitative prognosis of patients with pediatric brain tumors. However, multifaceted evaluations cannot be conducted in all patients because they are time consuming and burdensome for patients.
Ami Tabata, Keita Ueda, Tsukasa Ueno, Katsutsugu Umeda, Kentaro Ueno, Kanade Tanaka, Noyuri Nishida, Rie Yamawaki, Megumi Nukui, Yoshiki Arakawa   +9 more
wiley   +1 more source

Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors.

J Clin Endocrinol Metab
Araujo-Castro M, Menéndez Torre E, Lozano-Aida C, García-Centeno R, González Fernández L, Idrobo C, Achote-Rea E, Irigaray Echarri A, Rodríguez-Argulló MDM, Paja M, Guerrero-Pérez F, Castaño JP, Dolores Ollero García M, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabeu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Martín Rojas-Marcos P, Recio-Córdova JM, Aulinas A, Asla Roca Q, Aviles MD, López Mezquita E, Fernández-Argüeso M, González Molero I, Ruz-Caracuel I, Aldecoa I, García J, Martínez-Sáez E, Hanzu F, Marazuela M, Puig-Domingo M, Biagetti B.   +35 more
europepmc   +1 more source

Histopathological Types, Clinical Presentation, Imaging Studies, Treatment Strategies, and Prognosis of Posterior Pituitary Tumors: An Updated Review. [PDF]

J Clin Med
Iglesias P.
europepmc   +1 more source

Physiology of the hypothalamo-pituitary unit [PDF]

, 1978
Fahlbusch, R., Pickardt, C. R., Scriba, Peter Christian, Werder, Klaus von, Werder, Klaus von   +4 more
core   +1 more source

Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This review synthesises current knowledge on gut microbiome involvement in obesity and hypertension, evaluates microbiome‐based therapeutic strategies, and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics.
Andrej Belančić, Almir Fajkić, Yusuf Ziya Sener, Ana Jelaković, Lejla Alić, Elvira Meni Maria Gkrinia, Donatella Verbanac, Bojan Jelaković   +7 more
wiley   +1 more source